VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Mr. Peter Bull and Arbutus Distributors Ltd. (“Arbutus”), a private investment and holding company controlled by Mr. Bull, announced today that Mr. Bull and Arbutus disposed of an aggregate of 2,050,000 common shares (the “Subject Shares”) of ADENTRA Inc. (“ADENTRA”) at a sale price of $38.06 per Subject Share for aggregate gross proceeds of $78,023,000 on the Toronto Stock Exchange through a block sale on May 31, 2024 (the “Transaction”). ADENT ...

WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy. T ...

WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State or O ...

Financial Data and Key Metrics Changes - The company ended Q1 2024 with approximately $138 million in cash, cash equivalents, and investments, an increase from approximately $132 million as of December 31, 2023 [20] - During Q1 2024, the company received $21.8 million in net proceeds from the issuance of common shares, offset by $19.3 million used in operations [20] - The expected net cash burn for 2024 is projected to range between $63 million to $67 million, excluding any proceeds from the ATM program [20] Business Line Data and Key Metrics Changes - The company is advancing two proprietary clinical assets for HBV: imdusiran, an RNAi therapeutic, and AB-101, an oral small molecule PD-L1 checkpoint inhibitor [11] - Preliminary data from the Phase 1a/1b clinical trial of AB-101 is anticipated to be reported in the second half of 2024 [22] - The company has initiated patient screening for the AB-729-203 trial, evaluating imdusiran in combination with durvalumab [15] Market Data and Key Metrics Changes - Two abstracts from ongoing Phase 2a clinical trials were accepted for presentation at the EASL Congress in June 2024 [13] - The company is focused on developing a functional cure for chronic HBV, which involves reducing surface antigen, suppressing HBV DNA, and boosting the immune system [11][14] Company Strategy and Development Direction - The company aims to develop a functional cure for HBV through a combination of its clinical assets, with a focus on combination therapies [11][32] - The ongoing clinical trials are designed to evaluate the safety and efficacy of imdusiran in combination with various immunomodulatory approaches [14][15] - The company is also involved in ongoing patent infringement lawsuits to protect its intellectual property, including its LNP delivery technology [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's path towards developing a functional cure for HBV, highlighting the importance of ongoing clinical trials [8][11] - The company believes its cash runway is sufficient to fund operations through the second quarter of 2026, allowing for continued advancement of its HBV assets [21] Other Important Information - Dr. Mike Sofia, the Chief Scientific Officer, announced his retirement effective at the end of 2024, after co-founding the company over 10 years ago [7][8] - The company is currently evaluating the potential of AB-101 in a Phase 1a/1b clinical trial, with a focus on its unique liver-centric properties [17][19] Q&A Session Summary Question: When can functional cure signals be expected from the pipeline? - Management indicated that functional cure signals cannot be assessed until subjects are at least six months off all treatment, with ongoing trials expected to provide data as it becomes available [29] Question: What is the gating factor for starting a Phase 3 trial? - Management stated that the decision to start a Phase 3 trial will depend on the data from ongoing studies, including the new durvalumab trial and existing trials [30] Question: Will the next Phase 2b or Phase 3 study evaluate imdusiran as a monotherapy or in combination? - Management confirmed that the next study will likely focus on combination therapy, as curing HBV requires a multi-faceted approach [32] Question: What is the rationale behind different dosing intervals for durvalumab? - The rationale is to evaluate the extent of checkpoint inhibition necessary to induce HBV-specific immunity while maintaining a safe profile for patients [34] Question: What are the next steps for the AB-101 program after the multi-ascending dose Phase? - The next goal is to combine AB-101 with imdusiran in a Phase 2 study as quickly as possible after completing the current Phase 1 study [37]

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.12 per share when it actually produced a loss of $0.12, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Arbutus, which belongs to the Z ...

EXHIBIT 99.1 Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects Court provides claim construction ruling in ongoing patent infringement lawsuit against Moderna; Court da ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arbutus Biopharma (ABUS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Arbutus Biopharma is one of 1051 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different grou ...

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024. The schedule for the press release and conference call/webcast are as follows: •Q1 2024 Press Release:Thursday, ...

Core Viewpoint - Arbutus Biopharma Corporation is actively engaging with investors through participation in two upcoming conferences, highlighting its focus on developing a functional cure for chronic hepatitis B virus (cHBV) infection [1][2]. Group 1: Company Overview - Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company specializing in virology, aiming to develop novel therapeutics for chronic hepatitis B virus (cHBV) [2]. - The company’s strategy involves suppressing HBV DNA, reducing surface antigen, and enhancing HBV-specific immune responses to achieve a functional cure [2]. - Arbutus has a pipeline that includes proprietary compounds such as imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor [2]. Group 2: Clinical Trials - Imdusiran is currently undergoing two Phase 2a combination clinical trials, showing promising clinical data in reducing surface antigen and reawakening HBV-specific immune responses [2]. - AB-101 is in the Phase 1a/1b clinical trial stage, indicating ongoing development efforts for this compound [2]. Group 3: Investor Engagement - The management team of Arbutus will present at the Barclays 26th Annual Global Healthcare Conference on March 12, 2024, and will also participate in the Jefferies Biotech on the Bay Summit on March 13, 2024 [1]. - A live webcast of the Barclays conference presentation will be available, with an archived replay accessible on the Arbutus website for a limited time [1].